Rising Costs of Prescription Drug Plans for 2025
As the healthcare landscape shifts, employers are preparing for an 8 percent increase in medical plan costs, presenting a considerable challenge for 2025. This projection is based on a recent survey by Segal, a well-known benefits and HR consulting firm, which sheds light on employees' worries regarding rising healthcare expenses.
Factors Behind Increased Medical Expenses
The rising costs of medical plans are largely driven by price inflation. Healthcare providers, suppliers, and manufacturers are under pressure to maintain or enhance their profit margins as operational costs climb. The expected increase in medical expenses for next year could potentially break records, aside from a few exceptions during significant economic rebounds.
The Effect of GLP-1 Medications on Prescription Prices
One of the key factors behind the rising healthcare costs is the growing use of GLP-1 medications, which are recognized for their effectiveness in weight loss treatments. While these anti-obesity drugs show promise for short-term weight loss, their long-term health benefits still remain uncertain.
The Complexity of Cost-Benefit Analyses
When looking at the economic impact of anti-obesity medications (AOMs), the situation becomes more complicated. Their high prices and strong demand, particularly among lower-risk populations, make it difficult to evaluate their long-term economic benefits. The results of using these medications might take years or even decades to reflect in preventing severe health complications, which adds to the complexity for employers and health plans.
Employers Explore Strategies to Mitigate Costs
Given these challenges, the Segal survey suggests various cost management strategies that employers need to consider as they approach the new year. Many of these strategies specifically target managing the costs associated with GLP-1 medications. As organizations strive to navigate the complexities of covering these medications, they aim to be responsible stewards of their health benefit budgets.
Implementing Innovative Health Solutions
Health plans are increasingly looking into virtual tools and programs designed to manage chronic conditions. This comprehensive approach strives to improve patient outcomes while tackling rising costs. Moreover, there is a sense of optimism about the integration of biosimilars and customized prescription drug formularies into health plans, which could help create healthier financial outcomes for organizations.
The Role of Employers in Promoting Health Amid Rising Costs
As we approach 2025, Eric Miller, Vice President and Consulting Actuary at Segal, highlights that the main focus for health plans will be on addressing obesity and the use of anti-obesity medications. Employers want to provide extensive health benefits that promote healthier lifestyles; however, the high costs and varying timelines for assessing health outcomes present significant challenges.
Health plans need to optimize their use of GLP-1 medications, striking a balance between cost-efficiency and effective health interventions. This crucial issue is expected to become even more pressing in the coming years. Employers looking to encourage a healthier workforce while managing costs find themselves facing a complicated environment.
Insights from the Segal Survey
In its 28th year, the Segal survey provides vital insights based on proprietary data, assisting health plan sponsors in making informed decisions regarding rising costs. It emphasizes trend forecasts across different types of coverage, including medical, prescription drugs, dental, and vision, reflecting insights shared by 80 percent of the commercially insured market.
Recent Trends in Specialty Drug Costs
The trend for specialty drugs is estimated to rise up to 13.3 percent in 2025 as new, expensive medications come to market, phasing out more affordable alternatives. Furthermore, projections for dental provider organizations are set at 4.5 percent, while vision plans are predicted to increase by 3.0 percent.
Focus Areas for Health Plans
The Segal survey also highlights crucial areas such as cancer care services, evolving mental health service trends, and the impact of virtual consultations. Insights into prescription drug spending uncover leading therapeutic categories and most utilized drugs, thereby enhancing awareness for employers.
About Segal
Segal, founded in the financial consulting space, is dedicated to providing reliable advice aimed at improving lives. It operates as a full-service firm offering expertise across benefits, human capital, communications, technology, insurance brokerage, and investment consulting. With a team of over 1,000 employees throughout North America, Segal is committed to tackling the pressing issues employers face in managing employee health benefits.
Frequently Asked Questions
What are the expected medical plan cost increases for 2025?
The survey forecasts an 8 percent rise in medical plan costs for 2025, signaling growing challenges for employers.
How are GLP-1 medications affecting prescription drug costs?
GLP-1 medications are a significant factor in driving up prescription drug costs due to their effectiveness in weight loss combined with high demand and pricing.
What role do biosimilars play in health plan strategies?
Biosimilars are viewed as a practical option for health plans to manage costs without sacrificing effective treatment options for patients.
What are the top priorities for health plans in 2025?
Tackling obesity and effectively managing anti-obesity medications will be top priorities for health plans in 2025.
How does Segal's survey impact employer decision-making?
The insights from the Segal survey equip employers with valuable information to better manage healthcare costs.
